{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T12:44:40Z","timestamp":1749127480379,"version":"3.37.3"},"reference-count":20,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2006,6]]},"DOI":"10.1124\/dmd.105.005934","type":"journal-article","created":{"date-parts":[[2006,3,1]],"date-time":"2006-03-01T02:49:04Z","timestamp":1141181344000},"page":"906-912","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["ANTI-PHENCYCLIDINE MONOCLONAL ANTIBODY BINDING CAPACITY IS NOT THE ONLY DETERMINANT OF EFFECTIVENESS, DISPROVING THE CONCEPT THAT ANTIBODY CAPACITY IS EASILY SURMOUNTED"],"prefix":"10.1016","volume":"34","author":[{"given":"Grzegorz","family":"Pitas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth M.","family":"Laurenzana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. Keith","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Michael","family":"Owens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. Brooks","family":"Gentry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.105.005934_bib1","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.2042-7158.1997.tb06795.x","article-title":"Pharmacokinetics of heterologous and homologous immunoglobulin G, F(ab\u2032)2 and Fab after intravenous administration in the rat.","volume":"49","author":"Bazin-Redureau","year":"1997","journal-title":"J Pharm Pharmacol"},{"key":"10.1124\/dmd.105.005934_bib2","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/S1567-5769(01)00054-6","article-title":"A catalytic antibody against cocaine attenuates cocaine\u2019s cardiovascular effects in mice: a dose and time course analysis.","volume":"1","author":"Briscoe","year":"2001","journal-title":"Int Immunopharmacol"},{"key":"10.1124\/dmd.105.005934_bib3","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3109\/15563657608988151","article-title":"Perspectives: acute phencyclidine intoxication.","volume":"9","author":"Burns","year":"1976","journal-title":"Clin Toxicol"},{"key":"10.1124\/dmd.105.005934_bib4","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/S0022-3565(24)37498-1","article-title":"Pharmacodynamics of a monoclonal antiphencyclidine Fab with broad selectivity for phencyclidine-like drugs.","volume":"285","author":"Hardin","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.105.005934_bib5","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1124\/jpet.302.1.119","article-title":"A single dose of monoclonal anti-phencyclidine IgG offers long-term reductions in phencyclidine behavioral effects in rats.","volume":"302","author":"Hardin","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.105.005934_bib6","first-page":"841","article-title":"Chromodacryorrhea in laboratory rats (Rattus norvegicus): etiologic considerations.","volume":"30","author":"Harkness","year":"1980","journal-title":"Lab Anim Sci"},{"key":"10.1124\/dmd.105.005934_bib7","series-title":"New Treatments for Addiction: Behavioral, Ethical, Legal and Social Questions","first-page":"98","article-title":"What will we learn from the FDA clinical trials process and what will we still want to know about immunotherapies and depot medications to treat drug dependence?","author":"Kosten","year":"2004"},{"key":"10.1124\/dmd.105.005934_bib8","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1124\/jpet.103.053140","article-title":"Treatment of adverse effects of excessive phencyclidine exposure in rats with a minimal dose of monoclonal antibody.","volume":"306","author":"Laurenzana","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.105.005934_bib9","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0091-3057(00)00436-6","article-title":"Passive immunization against nicotine prevents nicotine alleviation of nicotine abstinence syndrome.","volume":"68","author":"Malin","year":"2001","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1124\/dmd.105.005934_bib10","doi-asserted-by":"crossref","first-page":"10176","DOI":"10.1073\/pnas.95.17.10176","article-title":"A catalytic antibody against cocaine prevents cocaine\u2019s reinforcing and toxic effects in rats.","volume":"95","author":"Mets","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/dmd.105.005934_bib11","series-title":"New Treatments for Addiction: Behavioral, Ethical, Legal and Social Questions","first-page":"63","article-title":"Vaccines and depot medications for drug addiction: rationale, mechanisms of action, and treatment implications","author":"Pentel","year":"2004"},{"key":"10.1124\/dmd.105.005934_bib12","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0091-3057(99)00206-3","article-title":"A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats.","volume":"65","author":"Pentel","year":"2000","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1124\/dmd.105.005934_bib13","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0022-3565(24)35360-1","article-title":"Anti-phencyclidine monoclonal antibodies provide long-term reductions in brain phencyclidine concentrations during chronic phencyclidine administration in rats.","volume":"292","author":"Proksch","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.105.005934_bib14","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/S0090-9556(24)15342-1","article-title":"The effect of rate of drug administration on the extent and time course of phencyclidine distribution in rat brain, testis and serum.","volume":"28","author":"Proksch","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.105.005934_bib15","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/ddr.10346","article-title":"The clinical pharmacology of therapeutic monoclonal antibodies.","volume":"61","author":"Roskos","year":"2004","journal-title":"Drug Dev Res"},{"key":"10.1124\/dmd.105.005934_bib16","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1037\/1064-1297.9.2.228","article-title":"Inhibition of nicotine-induced seizures in rats by combining vaccination against nicotine with chronic nicotine infusion.","volume":"9","author":"Tuncok","year":"2001","journal-title":"Exp Clin Psychopharmacol"},{"key":"10.1124\/dmd.105.005934_bib17","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0022-3565(25)38842-7","article-title":"Anti-phencyclidine monoclonal Fab fragments markedly alter phencyclidine pharmacokinetics in rats.","volume":"269","author":"Valentine","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.105.005934_bib18","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0022-3565(25)20654-1","article-title":"Antiphencyclidine monoclonal Fab fragments reverse phencyclidine-induced behavioral effects and ataxia in rats.","volume":"278","author":"Valentine","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.105.005934_bib19","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0022-3565(25)20655-3","article-title":"Antiphencyclidine monoclonal antibody therapy significantly changes phencyclidine concentrations in brain and other tissues in rats.","volume":"278","author":"Valentine","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.105.005934_bib20","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0090-9556(25)07214-9","article-title":"Chronic administration of phencyclidine: pharmacokinetic comparison of intravenous and subcutaneous infusions in Sprague-Dawley rats.","volume":"19","author":"Wessinger","year":"1991","journal-title":"Drug Metab Dispos"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624035037?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624035037?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.105.005934","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T18:06:27Z","timestamp":1739901987000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624035037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["S0090955624035037"],"URL":"https:\/\/doi.org\/10.1124\/dmd.105.005934","relation":{},"ISSN":["0090-9556"],"issn-type":[{"type":"print","value":"0090-9556"}],"subject":[],"published":{"date-parts":[[2006,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ANTI-PHENCYCLIDINE MONOCLONAL ANTIBODY BINDING CAPACITY IS NOT THE ONLY DETERMINANT OF EFFECTIVENESS, DISPROVING THE CONCEPT THAT ANTIBODY CAPACITY IS EASILY SURMOUNTED","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.105.005934","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2006 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}